Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05221138
Other study ID # VV116-03
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date December 30, 2021
Est. completion date January 19, 2022

Study information

Verified date January 2022
Source Vigonvita Life Sciences
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a single-center, randomized, open-label, three-period crossover design, the objective is to evaluate the pharmacokinetics and safety of VV116 tablets, which are orally administered to Chinese healthy volunteers after fasting, standard diet or high-fat diet.


Description:

12 healthy subjects will be enrolled once all eligibility criteria are met after screening within 14 days prior to investigation product administration. Informed consent should be obtained before any protocol defined procedures can be started. Investigational product administration plan given below: 12 healthy subjects will be randomized to 3 groups, i.e., Group A, Group B, Group C, with 4 subjects in each group. For group A, investigation product will be given after fasting for Period 1, after standard diet for Period 2, and after high-fat diet for Period 3; For group B, investigation product will be given after high-fat diet for Period 1, after fasting for Period 2, and after standard diet for Period 3; For group C, investigation product will be given after standard diet for Period 1, after high-fat diet for Period 2, and after fasting for Period 3. Wash-out period is 3 days.


Recruitment information / eligibility

Status Completed
Enrollment 12
Est. completion date January 19, 2022
Est. primary completion date January 19, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: 1. Healthy subjects between the ages of 18 and 45 years; 2. Body weight no less than 50 kg for male, no less than 45 kg for female; Body Mass Index of 19 to 26kg/m2; 3. Physical examination, vital signs examination, laboratory examination, ECG, B-ultrasound and fundus examination results were normal or abnormal without clinical significant; 4. Subjects who are willing to take proper contraceptive during the study and within 3 months after the study completed; 5. Subjects who are able to understand and follow study plans and instructions; Subjects who have voluntarily decided to participate in this study, and signed the informed consent form; Exclusion Criteria: 1. Subjects with hypersensitivity to VV116 or any of the excipients; 2. Subjects with allergic diseases or allergic constitution; 3. Subjects with central nervous system,cardiovascular system,gastrointestinal, respiratory system,urinary,Hematologic System,metabolic disorders that require medical intervention or other diseases (such as psychiatric history) that are not suitable for clinical trials; 4. Blood donation or blood loss = 400 mL within 3 months prior to inclusion, or have a history of blood product use history; 5. Participated in a clinical study involving another investigational drug within 3 month before the screening visit; 6. Taken any prescription drugs, non-prescription drugs, Chinese herbal medicine or health care products within 2 weeks prior to screening; 7. Drug or alcohol addicts within 1 year prior to screening, who drink at least twice a day or more than 14 units per week, or who are addicted to alcohol (1 unit ˜200 mL beer with 5% alcohol content, 25 mL spirits with 40% alcohol content or 85 mL wine with 12% alcohol content) ; 8. Those who smoke more than 10 cigarettes per day and do not agree to avoid using any tobacco products during the trial period; 9. Those who cannot quit smoking or drinking during the trial; 10. Those who are positive for hepatitis B surface antigen (HBsAg), HCV antibody, syphilis antibody and HIV antibody; 11. Abnormal and clinically significant chest radiographs (anteroposterior); 12. B ultrasound examination showed moderate to severe fatty liver; 13. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) exceeded the upper normal limit (ULN) at screening time or baseline; 14. Glomerular filtration rate (eGFR) < 90 mL/min/1.73m2 at screening time or baseline; 15. Abnormal ecg at screening or baseline, single QTcF (corrected for heart rate) > 450 ms in men, > 470 ms in women, and/or other clinically significant abnormalities; 16. Pregnant or lactating women or male subjects whose spouse has a child care plan within 3 months; 17. The investigator believes that there are other factors that are not suitable for participating in this trial.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
VV116
VV116 oral tablets, 400mg

Locations

Country Name City State
China Shanghai Xuhui Central Hospital Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Vigonvita Life Sciences

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluate high-fat diet and standard diet's effect on Cmax of VV116 tablets maximum observed plasma concentration From time zero up to 48 hours post-dose following oral administration of VV116
Primary Evaluate high-fat diet and standard diet's effect on AUC0-t of VV116 tablets area under the plasma concentration time curve from time zero to the last measurable concentration From time zero up to 48 hours post-dose following oral administration of VV116
Primary Evaluate high-fat diet and standard diet's effect on AUC0-8 of VV116 tablets area under the plasma concentration-time curve from time zero to infinity From time zero up to 48 hours post-dose following oral administration of VV116
Primary Evaluate high-fat diet and standard diet's effect on Tmax of VV116 tablets time at which Cmax occurs From time zero up to 48 hours post-dose following oral administration of VV116
Secondary The incidence and severity of treatment emergent adverse event (TEAE) of clinical symptoms The incidence and severity of treatment emergent adverse event (TEAE), including Serious Adverse Event (SAE), as well as clinical symptoms, and any abnormalities of vital signs, physical examinations, , ophthalmology and, etc. 7 days after last treatment
Secondary The incidence and severity of treatment emergent adverse event (TEAE) of vital signs The incidence and severity of treatment emergent adverse event (TEAE) of vital signs 7 days after last treatment
Secondary The incidence and severity of treatment emergent adverse event (TEAE)of physical examinations The incidence and severity of treatment emergent adverse event (TEAE)of physical examinations 7 days after last treatment
Secondary The incidence and severity of treatment emergent adverse event (TEAE) of laboratory tests The incidence and severity of treatment emergent adverse event (TEAE) of laboratory tests 7 days after last treatment
Secondary The incidence and severity of treatment emergent adverse event (TEAE) of physical examinations The incidence and severity of treatment emergent adverse event (TEAE) of physical examinations 7 days after last treatment
Secondary The incidence and severity of treatment emergent adverse event (TEAE) of electrocardiogram (ECG) The incidence and severity of treatment emergent adverse event (TEAE) of electrocardiogram (ECG) 7 days after last treatment
See also
  Status Clinical Trial Phase
Completed NCT05483998 - A Study to Evaluate Single and Multiple Doses of TLC-2716 in Healthy Participants Phase 1
Recruiting NCT02235012 - Cognitive Biases Under Ketamine N/A
Recruiting NCT02417714 - Prospective Evaluation of Next Generation CT Reconstruction (NextGenIR)
Completed NCT04418973 - Analysis of Breath Volatile Organic Compounds After Dyspnea Induced in the Healthy Subject. N/A
Completed NCT05088343 - Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Subjects Phase 1
Not yet recruiting NCT06248801 - Vildagliptin and Metformin Tablets 50/1000 mg Relative to GALVUS MET (50mg/1000 mg) Tablets Phase 1
Terminated NCT04068259 - Single Ascending Dose Study of PBI-4547 in Healthy Subjects Phase 1
Completed NCT03279302 - Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects Phase 1
Not yet recruiting NCT06233162 - Febuxostat 80 mg Tablets Relative to Feburic® 80 mg Tablets Phase 1
Recruiting NCT04159844 - Evaluation of the Stiffness and Pressure Applied on the Lower Leg by a New Compression Bandage on Healthy Subjects N/A
Completed NCT06137911 - Evaluation of Safety, Tolerability & Pharmacokinetics of JYP0061 in Healthy Adults. Phase 1
Completed NCT04849286 - Measurement of HTL0016878 in Cerebrospinal Fluid Phase 1
Not yet recruiting NCT06233227 - Dutasteride Soft Capsule 0.5 mg Relative to Avodart 0.5 mg Soft Capsule Phase 1
Completed NCT04096157 - A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants Phase 1
Completed NCT01200368 - Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants Phase 3
Recruiting NCT05805033 - Peri-Implant Soft Tissue Integration in Humans: Influence of Material N/A
Completed NCT04027803 - Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris® Phase 1
Recruiting NCT03467880 - Multicenter Study of Impulse Oscillometry in Chinese N/A
Completed NCT02903095 - Single Ascending Dose Study of TD-1439 in Healthy Subjects Phase 1
Active, not recruiting NCT02341508 - A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers Phase 1